Individualizing therapy: Do we have the tools to do it?

Journal of Diabetes

Volumn 7, Issue 1, 2015, Pages 1-2

  Shaw, Jonathan E ^a   Bloomgarden, Zachary T ^b  

^a BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIABETES MELLITUS; HUMAN; PERSONALIZED MEDICINE;

DIABETES MELLITUS; HUMANS; INDIVIDUALIZED MEDICINE;

EID: 84920000608     PISSN: 17530393     EISSN: 17530407     Source Type: Journal    
DOI: 10.1111/1753-0407.12218     Document Type: Editorial

References (5)

1. Bloomgarden ZT, Dodis R, Viscoli CM, Holmboe ES, Inzucchi SE. Lower baseline glycemia reduces apparent oral agent glucose-lowering efficacy: A meta-regression analysis. Diabetes Care. 2006; 29: 2137-2139.
2. Esposito K, Chiodini P, Bellastella G, Maiorino MI, Giugliano D. Proportion of patients at HbA1c target <7% with eight classes of antidiabetic drugs in type 2 diabetes: Systematic review of 218 randomized controlled trials with 78 945 patients. Diabetes Obes Metab. 2012; 14: 228-233.
3. Kim YG, Hahn S, Oh TJ, Kwak SH, Park KS, Cho YM. Differences in the glucose-lowering efficacy of dipeptidyl peptidase-4 inhibitors between Asians and non-Asians: A systematic review and meta-analysis. Diabetologia. 2013; 56: 696-708.
4. Monami M, Cremasco F, Lamanna C, Marchionni N, Mannucci E. Predictors of response to dipeptidyl peptidase-4 inhibitors: Evidence from randomized clinical trials. Diabetes Metab Res Rev. 2011; 27: 362-372.
5. Rosenstock J, Shenouda SK, Bergenstal RM etal. Baseline factors associated with glycemic control and weight loss when exenatide twice daily is added to optimized insulin glargine in patients with type 2 diabetes. Diabetes Care. 2012; 35: 955-958.